Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia

[1]  Lara E Sucheston-Campbell,et al.  Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. , 2021, Blood advances.

[2]  M. Heuser,et al.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party , 2021 .

[3]  B. Wood,et al.  Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML , 2020, Leukemia.

[4]  H. Deeg,et al.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Scott,et al.  Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies. , 2019, Critical reviews in oncology/hematology.

[6]  D. Sallman,et al.  Current status and new treatment approaches in TP53 mutated AML. , 2019, Best practice & research. Clinical haematology.

[7]  R. Schlenk,et al.  Targeting FLT3 mutations in AML: review of current knowledge and evidence , 2019, Leukemia.

[8]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Michael Stadler,et al.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.

[10]  E. Estey.  Acute myeloid leukemia: 2019 update on risk‐stratification and management , 2018, American journal of hematology.

[11]  S. Chanock,et al.  Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[13]  H. Dombret,et al.  SNP-array lesions in core binding factor acute myeloid leukemia , 2018, Oncotarget.

[14]  Hamid Bolouri,et al.  The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions , 2017, Nature Medicine.

[15]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[16]  R. Hehlmann.  Faculty Opinions recommendation of Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017 .

[17]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[18]  B. Wood,et al.  Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis , 2017, Haematologica.

[19]  Lara E Sucheston-Campbell,et al.  Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  E. Estey,et al.  Prognostic significance of acquired copy‐neutral loss of heterozygosity in acute myeloid leukemia , 2015, Cancer.

[21]  William Wheeler,et al.  Characterization of large structural genetic mosaicism in human autosomes. , 2015, American journal of human genetics.

[22]  E. Estey,et al.  Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  Robert K Hills,et al.  Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  N. Mounier,et al.  Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine , 2013, Blood Cancer Journal.

[26]  William Wheeler,et al.  Detectable clonal mosaicism and its relationship to aging and cancer , 2012, Nature Genetics.

[27]  M. McDevitt,et al.  New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Ringnér,et al.  Segmentation-based detection of allelic imbalance and loss-of-heterozygosity in cancer cells using whole genome SNP arrays , 2008, Genome Biology.

[29]  L. Möllgård,et al.  Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia , 2008, Leukemia & lymphoma.

[30]  F. Schmidt.  Meta-Analysis , 2008 .

[31]  G. Pamuk,et al.  17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis , 2007, Leukemia & lymphoma.

[32]  K. Gunderson,et al.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. , 2006, Genome research.